Skyrizi

Soln for inj 150 mg/mL: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Active psoriatic arthritis in adults who have an inadequate response or who have been intolerant to at least 1 prior DMARD. Moderate to severe palmoplantar pustulosis in adults who do not adequately respond or are intolerant to conventional therapy. Conc for soln for infusion 600 mg/10 mL & soln for inj 360 mg/2.4 mL: Adult patients w/ moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

SC Soln for inj 150 mg/mL Plaque psoriasis, psoriatic arthritis & palmoplantar pustulosis 150 mg at wk 0 & 4 & every 12 wk thereafter. Psoriatic arthritis May be used as monotherapy or in combination w/ non-biologic DMARDs. IV/SC Conc for soln for infusion 600 mg/10 mL & soln for inj 360 mg/2.4 mL Crohn's disease 600 mg IV infusion at wk 0, 4 & 8 followed by 360 mg SC inj at wk 12 & every 8 wk thereafter.

Hypersensitivity. Clinically important active infections (eg, active TB).

Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

L04AC18 - risankizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

POM